Barclays PLC Boosts Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)

Barclays PLC grew its position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 19.4% during the fourth quarter, Holdings Channel reports. The fund owned 91,634 shares of the company’s stock after purchasing an additional 14,904 shares during the period. Barclays PLC’s holdings in Inozyme Pharma were worth $254,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in shares of Inozyme Pharma in the 4th quarter worth about $38,000. Palumbo Wealth Management LLC increased its stake in shares of Inozyme Pharma by 52.3% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock valued at $64,000 after purchasing an additional 7,995 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Inozyme Pharma during the fourth quarter valued at approximately $68,000. JPMorgan Chase & Co. increased its stake in shares of Inozyme Pharma by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock valued at $151,000 after purchasing an additional 6,851 shares in the last quarter. Finally, BIT Capital GmbH bought a new position in shares of Inozyme Pharma during the fourth quarter valued at approximately $177,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Stock Performance

Shares of NASDAQ INZY opened at $1.16 on Monday. The firm’s 50-day moving average price is $1.03 and its 200-day moving average price is $1.96. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The company has a market cap of $74.89 million, a PE ratio of -0.74 and a beta of 1.35. Inozyme Pharma, Inc. has a 52-week low of $0.72 and a 52-week high of $6.24.

Analyst Ratings Changes

A number of brokerages have weighed in on INZY. Wells Fargo & Company decreased their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Inozyme Pharma in a research note on Tuesday, April 8th. Raymond James decreased their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Inozyme Pharma in a research note on Thursday, April 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 target price (down previously from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.63.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.